HR+/HER2-locally advanced or metastatic Breast Cancer Ibrance® MyTherapy App: Digital Therapy Support with comprehensive Functions for Breast Cancer Patients

被引：0
|
作者：
不详
机构：
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷 / 7-8期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：344 / 344
页数：1
相关论文
共 50 条
  • [1] First-line treatment patterns in HR+/HER2-locally advanced or metastatic breast cancer in Europe
    Lewis, K.
    Kurosky, S.
    Last, M.
    Mitra, D.
    Lambert, A.
    Mahtani, R.
    ANNALS OF ONCOLOGY, 2020, 31 : S371 - S372
  • [2] Real-world safety and effectiveness of ribociclib in Korean patients with HR+/HER2-locally advanced or metastatic breast cancer
    Kim, J. H.
    Chang, M-C.
    Kim, T-H.
    Seo, J. H.
    Kim, J-J.
    Won, H. S.
    Seong, M-K.
    Kang, Y.
    Lee, Y.
    Lee, K-H.
    ANNALS OF ONCOLOGY, 2024, 35 : S1419 - S1420
  • [3] HR+/HER2-locally advanced or metastatic Breast Cancer "I am observing a high level of Patient Satisfaction"
    不详
    BREAST CARE, 2018, 13 (04) : 303 - 303
  • [4] HR+/HER2-locally advanced or metastatic Breast Cancer 5-Year Data underline the Efficacy of Palbociclib (IBRANCE®) in Combination with Letrozole in First-line Treatment
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 (06)
  • [5] Ribociclib in HR+/HER2-Advanced or Metastatic Breast Cancer Patients
    Rascon, Kaitlin
    Flajc, Goran
    De Angelis, Carmine
    Liu, Xinli
    Trivedi, Meghana V.
    Ekinci, Ekim
    ANNALS OF PHARMACOTHERAPY, 2019, 53 (05) : 501 - 509
  • [6] A phase II study of fulvestrant combined with chemotherapy in the neoadjuvant treatment of HR+/HER2-locally advanced breast cancer
    Wu, J.
    Shao, Q.
    Pan, X.
    Zhou, W.
    Wang, Y.
    Zhang, N.
    Zhou, X.
    Li, W.
    Xu, F.
    Zeng, X.
    ANNALS OF ONCOLOGY, 2023, 34 : S328 - S328
  • [7] Treatment sequencing in HR+/HER2-locally advanced or metastatic breast cancer: A real-world retrospective study in France, Germany, Italy and Spain
    Lewis, K.
    Kurosky, S.
    Last, M.
    Mitra, D.
    Lambert, A.
    Mahtani, R.
    ANNALS OF ONCOLOGY, 2020, 31 : S375 - S376
  • [8] A phase I/II trial of palbociclib, pembrolizumab, and endocrine therapy for patients with HR+/HER2-locally advanced or metastatic breast cancer (MBC): Clinical outcomes and stool microbial profiling
    LeVee, Alexis Ann
    Egelston, Colt A.
    Yost, Susan Elaine
    Frankel, Paul Henry
    Lee, Keehoon
    Ruel, Christopher
    Schmolze, Daniel
    Lee, Peter P.
    Yeon, Christina Haeyoung
    Yuan, Yuan
    Waisman, James Ross
    Pal, Sumanta Kumar
    Mortimer, Joanne E.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [9] TREATMENT PATTERNS AND PROGNOSTIC FACTORS OF LOCALLY ADVANCED OR METASTATIC HR+ / HER2-BREAST CANCER IN ARGENTINA
    Novick, D.
    Moneta, M., V
    Fischman, M.
    Zarino, N.
    Gallino, J.
    Carter, Cuyun G.
    Haro, J. M.
    VALUE IN HEALTH, 2020, 23 : S62 - S63
  • [10] WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT AMONG PATIENTS WITH HR+/HER2-LOCALLY ADVANCED OR METASTATIC BREAST CANCER IN FRANCE, GERMANY, ISRAEL, ITALY, SPAIN, AND THE UNITED STATES
    Mahtani, R.
    Lewis, K.
    Lambert, A.
    Last, M.
    Mitra, D.
    Bambrick, C.
    Kurosky, S.
    VALUE IN HEALTH, 2020, 23 : S476 - S476
12345